The Week Ahead: Fed...
Health Care: Drugs
Exact Sciences Corporation (EXAS: NASDAQ)
$9.55 -0.10 | -1.04%
06/04/12 - 12:25 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -28.68M | -11.56M | -9.13M | -9.74M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -263.00K | 873.00K | -528.00K | 438.00K |
| (Decrease) Increase In Other Current Liabilities | 1.27M | 687.00K | -81.00K | -1.29M |
| (Increase) Decrease In Other Working Capital | 0.00 | -988.00K | -7.19M | 2.25M |
| Other Non-Cash Items | 4.36M | 2.36M | 4.41M | 1.08M |
| Net Cash From Continuing Operations | -27.82M | -13.48M | -12.64M | -7.90M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -27.82M | -13.48M | -12.64M | -7.90M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 274.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 46.08M | 10.24M | 16.47M | 11.54M |
| Purchases of Property, Plant & Equipment | -2.12M | -626.00K | -462.00K | -104.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -87.02M | -24.50M | -18.88M | -3.46M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -43.05M | -14.88M | -2.87M | 8.25M |
| Issuance of Debt | 0.00 | 0.00 | 1.00M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 27.90M | 82.79M | 14.79M | 66.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 2.40M | 16.70M | 41.00K |
| Net Cash From Financing Activities | 27.90M | 85.19M | 32.49M | 107.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -42.97M | 56.83M | 16.99M | 451.00K |
Portfolios with EXAS
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- Contributor8 Health Care Stocks With R...
- Usergdean1
- Userradforj John's SEP & Ta...
- UserBlind Rookie
- Userbbrads Portfolio 1
- Userremodelit Portfolio 1
- UserGoBears Under $5 Stock Picks
- UserMornan
- Userjwpao Portfolio 1
Latest EXAS Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- Look to Exact Sciences, Not Radient Pharma, for Best Colon Cancer Screen Test 01.23.12 | 01:01 pm
- Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12.09.11 | 06:12 am
- Exact Sciences Corporation (EXAS): CORRECTION 10.06.11 | 04:10 pm
- Exact Sciences' Colon Cancer Screening Trial 07.12.11 | 08:07 am
- 8 Health Care Stocks With Recent Gains 06.29.11 | 02:06 pm
- Biotech Stock Mailbag: Neoprobe 05.06.11 | 07:05 am
- Radient Pharma Readies Onko-Sure Data 03.29.11 | 02:03 pm
- Mayo Clinic Denies Test Link to Radient Pharma 03.07.11 | 05:03 pm
- Biotech Stock Mailbag: Exact Sciences 02.25.11 | 07:02 am
Press Releases for EXAS
- Exact Sciences To Participate In June Investor Conferences - Business Wire 05.30.12 | 10:05 am
- Exact Sciences Extends, Expands Relationship With Mayo Clinic - Business Wire 05.17.12 | 09:05 am
- Exact Sciences To Participate In May Investor Conferences - Business Wire 05.07.12 | 11:05 am
- Exact Sciences Reports First-Quarter 2012 Financial Results - Business Wire 05.01.12 | 07:05 am
- Exact Sciences To Host First-Quarter 2012 Results Webcast And Call - Business Wire 04.23.12 | 02:04 pm
- Exact Sciences’ Executives, Colon Cancer Challenge Leaders To Ring Nasdaq Opening Bell - Business Wire 03.19.12 | 09:03 am
- Exact Sciences To Participate In March Investor Conferences - Business Wire 02.29.12 | 11:02 am
- Exact Sciences Reports Fourth-Quarter, Full-Year 2011 Financial Results - Business Wire 02.23.12 | 07:02 am
- Exact Sciences Announces Appointment Of Stoltenberg As Chief Commercial Officer - Business Wire 02.20.12 | 04:02 pm
- Exact Sciences Promotes Arora To Chief Operating Officer - Business Wire 02.16.12 | 04:02 pm
Partner Headlines for EXAS
- UPDATE: Auriga Raises PT to $13 on EXACT Sciences - Benzinga 02.24.12 | 04:02 pm
- Exact Sciences Promotes Arora to Chief Operating Officer - Benzinga 02.16.12 | 04:02 pm
- 10 Undervalued Biotech Stocks With Insider Buying - Seeking Alpha 06.23.11 | 06:06 am
- Momentum Ideas: Friday's High Volume Gainers Chased by Big Money Managers - Seeking Alpha 04.17.11 | 07:04 am
- Cramer's Mad Money - 6 Earnings and IPOs to Watch for the Coming Week (4/8/11) - Seeking Alpha 04.10.11 | 04:04 am
- Life Science Portfolios: Reflecting on a Year of Out-Performance - Seeking Alpha 12.29.10 | 05:12 am
- UPDATE1-New colon cancer test works without colonoscopy - Reuters 10.28.10 | 05:10 pm
- Detecting More Upside Potential for EXACT Sciences - Seeking Alpha 10.22.10 | 09:10 pm
- Piper Jaffray’s Top Picks for The Second Half of 2010 (CPHD, EXAS, GNMK) - Benzinga 08.24.10 | 09:08 am
- 6 Ways to Trade FDA and Clinical Trial News - Seeking Alpha 05.28.10 | 02:05 pm
